Bivalent killed whole-cell oral cholera vaccine,
does it really help with Prevention of clinical cholera in residents of and travelers to cholera-affected areas?
research showsBivalent killed whole-cell oral cholera vaccine is rated B for preventing clinical cholera in cholera-affected settings. A cluster-randomized double-blind placebo-controlled trial of 107,774 residents in Kolkata directly assessed culture-confirmed cholera and found about 67% cumulative efficacy at two years and 65% at five years among fully vaccinated recipients. A 2017 meta-analysis estimated average two-dose efficacy at about 58%. Evidence is concentrated in endemic or outbreak populations, protection is lower in young children, and direct clinical-outcome evidence in travelers is limited, yielding A with 83 points.
ads claimPopulation-level effects in endemic settings can be expanded into identical magnitude and duration for every traveler, or one dose can be portrayed as complete long-term protection. Actual protection varies with dose schedule, age, exposure intensity, and time since vaccination.
Useful facts when choosing a product
- Euvichol-family products are oral prescription vaccines containing killed whole cells of Vibrio cholerae O1 and O139 and are not live vaccines.
- The pivotal Kolkata efficacy trial evaluated two doses given 14 days apart and adjudicated clinical disease by culture-confirmed diarrhea.
- Protection was directly shown in endemic or outbreak settings, was lower in children younger than five years, and has limited direct clinical-trial evidence in travelers.
- Adverse effects are generally mild gastrointestinal symptoms such as abdominal discomfort, diarrhea, nausea, and vomiting, without a clear placebo-controlled increase in serious events.
What the research actually shows
The 2009 Kolkata trial by Sur cluster-randomized 107,774 nonpregnant residents aged at least one year by dwelling to two vaccine doses or heat-killed Escherichia coli K12 placebo. The primary endpoint was culture-confirmed Vibrio cholerae O1 diarrhea severe enough to lead to treatment, with cumulative efficacy of about 67% at two years. Five-year follow-up by Bhattacharya found 69 cases among 31,932 vaccine recipients and 219 among 34,968 placebo recipients, for 65% cumulative efficacy. The 2017 meta-analysis by Bi estimated average two-dose efficacy at 58% and confirmed variation by age and time. WHO evidence assessments support killed oral vaccination in endemic, high-risk humanitarian, and outbreak settings.
Why this is classified as A (83)
Large cluster-randomized, double-blind, placebo-controlled field trials directly reduced culture-confirmed clinical cholera with 65% cumulative protection at five years, and WHO rated efficacy and effectiveness with high confidence based on eleven randomized trials. Because multiple independent large trials reproduced the hard endpoint of disease occurrence, this is A with 83 points; lower effect in children under five, duration of protection, and limited direct traveler evidence are noted as scope limits.
Counterpoint. This verdict is limited to prevention of cholera with bivalent killed whole-cell oral vaccine. Evidence from other cholera platforms or vaccines against influenza, rotavirus, or Japanese encephalitis was not combined.
Rejudgment record. Cross-check applied — At cross-check the B draft was raised to A (83 points) to reflect reproduction across multiple large independent placebo-controlled field trials measuring culture-confirmed clinical cholera and WHO's high confidence; lower efficacy under age five, duration of protection, and limited direct traveler evidence are stated separately as scope limits.
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Prevention of culture-confirmed clinical cholera in residents of affected areas | A | A large cluster-randomized placebo-controlled trial and long-term follow-up directly confirmed fewer clinical cases. |
| Indirect population protection in areas with high vaccine coverage | A | Cluster-trial reanalyses and field data support the effect, but it is distinct from individually randomized protection. |
| Prevention of clinical cholera in travelers to affected areas | C | Biological and resident-population efficacy evidence exists, but direct clinical-outcome data in travelers are limited. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Sur D et al. 2009 | Cluster-randomized double-blind placebo-controlled trial | 107,774 | Bill & Melinda Gates Foundation and public or academic institutions | Culture-confirmed cholera severe enough to prompt health-care attendance | Cumulative efficacy at two years was about 67% among fully vaccinated recipients. | Pivotal large direct trial |
| Bhattacharya SK et al. 2013 | Five-year follow-up of the same cluster-randomized placebo-controlled trial | 34,968 | Bill & Melinda Gates Foundation and Swedish International Development Cooperation Agency | Cumulative culture-confirmed cholera over five years | There were 69 versus 219 cases, for cumulative efficacy of 65% (95% CI 52 to 74). | Direct durability evidence |
| Bi Q et al. 2017 | Systematic review and meta-analysis | 6 | Bill & Melinda Gates Foundation | Efficacy and field effectiveness against culture-confirmed cholera | Average two-dose efficacy was 58%, with lower protection in children younger than five years. | Key synthesis |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-23).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-23 · Corrections: none
Cite this verdict
[Chamgap] Bivalent killed whole-cell oral cholera vaccine x prevention of clinical cholera — Evidence Grade A·83. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/bivalent-killed-whole-cell-oral-cholera-vaccine-clinical-cholera-prevention/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.